Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 4/19/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Mitchell Gold?

Mitchell H. Gold

Executive Chairman and Chief Executive Officer

Alpine Immune Sciences , Inc.

HQ Phone:  (206) 788-4545

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Alpine Immune Sciences , Inc.

201 Elliott Avenue West Suite 230

Seattle, Washington,98119

United States

Company Description

Alpine Immune Sciences (AIS) was founded in 2015 and is focused on developing novel protein?based immunotherapies using its proprietary variant immunoglobulin domain (vIgD) platform technology. The vIgD platform, unlike other therapeutic approaches in developm... more

Find other employees at this company (13)

Background Information

Employment History

Founder and Chairman

Alpine Biosciences


Chief Executive Officer and President

Lead411


Chief Executive Officer

Puget Sound Business Journal


Chief Executive Officer

Ernst & Young LLP


President and Chief Executive Officer

Shareholder.com incorporated


President and Chief Executive Officer

Dendreon Corporation


Affiliations

University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute

Board Member


Affiniscape Inc

Board Member


Phacilitate Limited

Advisory Board Member


Washington Biotechnology & Biomedical Association

Board Member


Biotechnology Industry Organization

Chief Executive Officer


InvestorVillage

Board Member


Info.Resource , Inc.

Board Member


Xenotope Diagnostics Inc.

Board Member


Immunex Corporation

Co-Founder


Catalyst Medical Solutions

Board Member


PE Hub

Board Member


Jennerex , Inc.

Board Member


ICOS Corporation

Co-Founder


Education

B.S.

University of Wisconsin-Madison


M.D.

Cancer Research Institute


M.D.

Rush Medical College


MD/PhD/CEO of Dendreon


Web References(178 Total References)


About Us | Alpine Immune Sciences

www.alpineimmunesciences.com [cached]

Mitchell H. Gold, MD
Executive Chairman & Acting CEO Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer, stemming from the loss of his 26-year old mother to metastatic breast cancer when he was four years old. This loss served as the catalyst for Dr. Gold's career in medicine and desire to transform scientific breakthroughs into a reality for patients. As CEO of Dendreon Corporation, Dr. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient's own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010. Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Oncothyreon (NASDAQ:ONTY) in August 2014. For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for "Smartest CEO" by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. Dr. Gold is currently the founder and managing partner of Alpine BioVentures. Dr. Gold is on Twitter @Alpine_Mitch Mitchell H. Gold, MD Executive Chairman & Acting CEO Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer. As CEO of Dendreon Corporation, Dr. Mitchell H. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient's own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010. Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Oncothyreon (NASDAQ:ONTY) in August 2014. For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for "Smartest CEO" by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. Dr. Gold is currently the founder and managing partner of Alpine BioVentures. Dr. Gold is on Twitter @Alpine_Mitch


Stock Market News - Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger

updown.com [cached]

Alpine Immune Sciences, a cancer immunotherapy company founded by former Dendreon CEO Mitch Gold, is listing publicly through a merger with Nivalis Therapeutics.


globalpharmaupdate.com

Mitchell H. Gold, M.D., Managing Partner at Alpine BioVentures, will serve as AIS' Executive Chairman and acting Chief Executive Officer.
AIS is taking a unique approach to modulating the immune system through the directed evolution of naturally occurring ligands - creating the next generation of cancer and autoimmune therapeutics with our vIgD™ platform," said Mitchell H, Gold, M.D., Alpine Immune Sciences' Executive Chairman and acting CEO.


Alpine Immune Sciences Grabs $48M Series A

www.vcnewsdaily.com [cached]

Mitchell H. Gold, M.D., Managing Partner at Alpine BioVentures, will serve as AIS' Executive Chairman and acting Chief Executive Officer.
AIS is taking a unique approach to modulating the immune system through the directed evolution of naturally occurring ligands - creating the next generation of cancer and autoimmune therapeutics with our vIgD? platform,' said Mitchell H, Gold, M.D., Alpine Immune Sciences' Executive Chairman and acting CEO. 'We believe this significant funding, along with our collective expertise, will enable us to discover and develop clinically meaningful and transformative therapies for patients.'


Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies | Business Wire

feeds.businesswire.com [cached]

Mitchell H. Gold, M.D., Managing Partner at Alpine BioVentures, will serve as AIS' Executive Chairman and acting Chief Executive Officer.
AIS is taking a unique approach to modulating the immune system through the directed evolution of naturally occurring ligands - creating the next generation of cancer and autoimmune therapeutics with our vIgD platform," said Mitchell H, Gold, M.D., Alpine Immune Sciences' Executive Chairman and acting CEO.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory